adakveo
(crizanlizumab)Novartis Pharmaceuticals Corporation
Usage: ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.
5 results
droxia
(HYDROXYUREA)H2-Pharma LLCUsage: DROXIA is indicated for reducing the frequency of painful crises and minimizing the need for blood transfusions in patients with sickle cell anemia who experience recurrent moderate to severe painful crises.ferriprox
(deferiprone)Chiesi USA, Inc.Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for myelodysplastic syndrome or Diamond Blackfan anemia.ferriprox
(deferiprone)Chiesi USA, Inc.Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for use in myelodysplastic syndrome or Diamond Blackfan anemia.siklos
(hydroxyurea)MedunikUsage: SIKLOS® is indicated for reducing the frequency of painful crises and the need for blood transfusions in adults and pediatric patients, 2 years and older, suffering from sickle cell anemia with recurrent moderate to severe painful crises.